European Facility Updates from Consort Medical

New oral liquids facility at Pianezza: and enhanced blister and packaging line at Monheim

Hemel Hempstead, UK – Consort Medical, Aesica CDMO Services, announces key facility updates for manufacturing and packaging solutions at both its Pianezza and Monheim sites.

The redesigned oral liquids facility, at Pianezza, features the latest Marchesini equipment and will double the production capacity of oral formulated drugs to 28 million bottles per year. Qualification and validation activities will be taking place during Q4 2018 and, following receipt of the necessary local authorizations, the facility will be ready to start production in Q1 2019.

Responding to customer demand, the facility has been further equipped with new dissolution equipment to allow the production of a wider variety of oral solutions, including emulsions. The line is fully serialization ready and equipped with an innovative process monitoring system to support enhanced efficiency and quality.

The new double row blister and carton packaging line in Monheim has been designed by Uhlmann. This enhanced capability will come online in Q1 2019, following qualification, validation and receipt of regulatory approvals. The blister line will consist of a fully automated serialization station as well as an online integrated case packer. Due to its smart design and use of the latest technology, and enables rapid autonomous tool changing at the machine.
The machine has a capacity of up to 500 blisters and 300 boxes per minute and can blister all common materials, i.e. alumina, PVC and PP. Blister filling is checked by an optical camera system and can be printed online with art work.

“Ensuring high standards of quality and efficiency are key elements in our delivery of Industry 4.0,” commented Manja Boerman, President Aesica CDMO Services, Consort Medical. “Our serialization technology is delivering full GMP-compliance for the European market, addressing anti-counterfeiting and fraud. Equipping our production lines with fully integrated serialization solutions and the latest process monitoring technologies are crucial.”

Aesica are exhibiting at CPhI/ICSE 2018, which is taking place at IFEMA, Feria de Madrid, Spain on 9th  - 11th October 2018. For more information, visit:

- ENDS -

About Consort Medical plc

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses:

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

We employ approximately 2,000 people globally of which approximately 1,400 are located in the UK. We have UK facilities in King’s Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT).

Issued for and on behalf of Consort Medical plc by Instinctif Partners. 
For more information please contact:

Nicola Newcombe
Sales and Marketing Coordinator
T: +44 1553 693647

Back to news